Evido offers an AI-powered diagnostic platform for the early detection and risk stratification of chronic liver disease. By analyzing routine patient data, the platform identifies individuals at high risk, enabling timely intervention and optimized patient pathways for primary care physicians.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), is a widespread and often asymptomatic condition affecting approximately one in four individuals globally. The lack of early detection means many patients are diagnosed only at advanced, irreversible stages, leading to poor prognoses and significant mortality. Current diagnostic pathways are often inefficient, relying on specialist referrals that are frequently delayed or unnecessary, thus straining healthcare resources.
Solution
Evido provides a data-driven diagnostic platform designed for the early detection and risk stratification of chronic liver disease. Leveraging existing patient data, including routine blood sample results, Evido's proprietary algorithms identify individuals at high risk for liver conditions. This enables timely intervention and optimized patient pathways, shifting the paradigm towards proactive management and prevention. The platform integrates seamlessly with existing healthcare information systems, providing actionable clinical recommendations to non-specialist clinicians at the point of care. This approach aims to improve patient outcomes by facilitating earlier treatment and reducing the burden on specialized healthcare professionals.
Target Audience
Primary customers include primary care physicians, specialist hepatologists, hospital networks, and healthcare systems seeking to improve the early detection and management of chronic liver diseases.
Features
- AI-powered risk stratification models trained on extensive clinical research and patient data for accurate identification of at-risk individuals.
- Utilizes standard blood sample results and other routinely collected patient data for non-invasive assessment.
- Provides actionable clinical recommendations and specialized liver knowledge to primary care physicians and non-specialist clinicians.
- Integrates with existing healthcare information systems and diagnostic workflows to facilitate adoption and scalability.
- Offers automated assessment of liver referrals to specialized clinics, reducing redundant consultations and optimizing specialist utilization.
- CE-marked software solution (LiverPRO) for the detection and management of steatotic liver disease.
- Compliant with ISO 13485 quality management system standards.